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ABSTRACT There are marked differences in the spread and prevalence of HIV-1
subtypes worldwide, and differences in clinical progression have been reported.
However, the biological reasons underlying these differences are unknown. Gag-protease
is essential for HIV-1 replication, and Gag-protease-driven replication capacity has
previously been correlated with disease progression. We show that Gag-protease
replication capacity correlates significantly with that of whole isolates (r  0.51; P 
0.04), indicating that Gag-protease is a significant contributor to viral replication ca-
pacity. Furthermore, we investigated subtype-specific differences in Gag-protease-
driven replication capacity using large well-characterized cohorts in Africa and the
Americas. Patient-derived Gag-protease sequences were inserted into an HIV-1 NL4-3
backbone, and the replication capacities of the resulting recombinant viruses were
measured in an HIV-1-inducible reporter T cell line by flow cytometry. Recombinant
viruses expressing subtype C Gag-proteases exhibited substantially lower replication
capacities than those expressing subtype B Gag-proteases (P  0.0001); this observa-
tion remained consistent when representative Gag-protease sequences were engi-
neered into an HIV-1 subtype C backbone. We identified Gag residues 483 and 484,
located within the Alix-binding motif involved in virus budding, as major contribu-
tors to subtype-specific replicative differences. In East African cohorts, we observed a
hierarchy of Gag-protease-driven replication capacities, i.e., subtypes A/C  D  in-
tersubtype recombinants (P  0.0029), which is consistent with reported intersub-
type differences in disease progression. We thus hypothesize that the lower Gag-
protease-driven replication capacity of subtypes A and C slows disease progression
in individuals infected with these subtypes, which in turn leads to greater opportu-
nity for transmission and thus increased prevalence of these subtypes.
IMPORTANCE HIV-1 subtypes are unevenly distributed globally, and there are re-
ported differences in their rates of disease progression and epidemic spread. The bi-
ological determinants underlying these differences have not been fully elucidated.
Here, we show that HIV-1 Gag-protease-driven replication capacity correlates with
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the replication capacity of whole virus isolates. We further show that subtype B dis-
plays a significantly higher Gag-protease-mediated replication capacity than does
subtype C, and we identify a major genetic determinant of these differences. More-
over, in two independent East African cohorts we demonstrate a reproducible hierar-
chy of Gag-protease-driven replicative capacity, whereby recombinants exhibit the
greatest replication, followed by subtype D, followed by subtypes A and C. Our data
identify Gag-protease as a major determinant of subtype differences in disease pro-
gression among HIV-1 subtypes; furthermore, we propose that the poorer viral repli-
cative capacity of subtypes A and C may paradoxically contribute to their more effi-
cient spread in sub-Saharan Africa.
KEYWORDS HIV-1 subtype, Gag-protease, viral replication capacity
HIV-1 group M accounts for greater than 95% of HIV infections worldwide (1, 2). Itis considerably genetically diverse, consisting of 9 subtypes (A to D, F to H, J, and
K) and over 70 circulating recombinant forms (CRFs), which are unevenly distributed
globally (2–5). Subtype B, which predominates in the Americas, Europe, and Australia
(3), is the best-characterized subtype; however, it accounts for only approximately 11%
of infections (6). On the other hand, subtypes A, C, and D and intersubtype recombi-
nants predominate in sub-Saharan Africa (2), which carries about 70% of the global
burden of HIV-1 disease (7). In particular, HIV-1 subtype C, which is the most prevalent
subtype globally (50% of infections), is responsible for nearly all HIV-1 infections in
Southern Africa and the Ethiopia/Somalia region; it has also gained dominance in
several east Asian countries and is the fastest-emerging subtype in South America (2,
8). Moreover, subtypes A and D and intersubtype recombinants predominate in East
and Central Africa (2, 3); subtype A in particular has significantly increased in frequency
in Uganda (9).
Differences in the rates of disease progression and transmission between HIV-1
subtypes could contribute to their differing prevalence and expansion. Studies in East
Africa, where subtypes A and D cocirculate, have established that subtype D is
associated with faster disease progression than subtype A (10–13). There is also
evidence that recombinant forms have a higher rate of progression to AIDS than does
subtype A (10, 14), although this was not observed in another study (12). There are
conflicting reports regarding the rate of disease progression of subtype C relative to
that of other subtypes (12, 15–18). While there is general agreement that subtype C has
a transmissibility rate at least equal to those of other M group subtypes (19, 20), some
studies have reported increased transmissibility of subtype C compared to subtypes A
and D (21–23). Furthermore, the higher heterosexual transmission of subtype A than of
subtype D (24) may have contributed to the expansion of subtype A in Uganda (9).
Differential prevalence and expansion of subtypes have important implications for
future projections of the pandemic and for the development of vaccines and other
preventative or therapeutic strategies. However, the biological reasons underlying
these differences remain unclear. Ex vivo competition assays of limited numbers of viral
isolates have indicated that recombinant viruses are fitter than their parental forms (25,
26) and that subtype C (from Africa) is substantially less fit than subtypes A, B, and D
(19, 20, 27), although more isolates are required to delineate differences between
subtypes A, B, and D (20). Although in vitro viral replication has been correlated with
disease progression in some studies (28), the relationship between these factors
remains incompletely characterized. Furthermore, biological differences between sub-
type C and subtype B and/or other subtypes in the Env (29), reverse transcriptase (30),
protease (31), Vif (32), and long terminal repeat (LTR) regions (33, 34) have been
reported; however, the implications of these factors for disease progression and
epidemic spread remain unclear. More recently, a study of 100 clinical isolates
showed that subtype D had higher Pol-driven replication capacity than subtype A and
directly linked these differences to faster disease progression in the former than in the
latter subtype (35). Furthermore, we recently demonstrated subtype-specific differ-
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ences in Nef function (36) and showed that Nef functional differences in acute infection
correlate with markers of disease progression (37). Taken together, these results
support subtype-specific differences in HIV-1 protein function as determinants of
disease progression.
We and others have demonstrated that Gag-protease (Gag-Pro) or Gag-driven
replication capacity correlates with markers of disease progression (38–41). Given the
evidence of Gag as a determinant of disease progression and the important role of Gag
in HIV-1 replication (reviewed in reference 42), we sought to determine whether there
are subtype-specific differences in Gag-protease-driven replication capacity using well-
pedigreed clinical cohorts from Africa and the Americas. We first assessed the contri-
bution of Gag-protease to the overall viral replicative capacity and demonstrated that
the former reflects the latter. We next compared the Gag-protease-driven replication
capacities of subtype B and C isolates derived from different geographical locations and
determined that subtype C isolates have substantially lower replication capacity than
subtype B isolates. Furthermore, we identified the genetic determinants of these
differences. To further elucidate subtype-specific Gag-protease biological differences
and whether they contribute to intersubtype differences in disease progression, we
measured Gag-protease-driven replication capacity in a population where subtypes A,
C, and D and intersubtype recombinants cocirculate. A hierarchy of Gag-protease-
driven replication capacities that was consistent with reported intersubtype differences
in disease progression was found. We discuss possible implications of these results in
light of reported subtype differences in disease progression and epidemic spread.
RESULTS
Gag-protease-driven replication capacity correlates with replication capacity
of whole virus isolates. Previous studies have demonstrated that Gag-protease-driven
replication capacity correlates with markers of disease progression, namely, plasma viral
load, CD4 T cell counts, and the rate of CD4 T cell decline (38–41). To determine the
contribution of Gag-protease to the overall HIV-1 replication capacity, we compared the
in vitro replication of whole patient-derived HIV-1 isolates with that of their respective
Gag-protease NL4-3 recombinant viruses for 16 chronic subtype C-infected individuals
from the South African Sinikithemba (SK) cohort. There was a tendency for the
recombinant viruses to have higher replication capacity than the isolates; nevertheless,
a statistically significant correlation was found between them (Pearson’s correlation, r
0.51 and P  0.04) (Fig. 1). This confirms that Gag-protease contributes significantly to
overall viral replication capacity.
Subtype C Gag-protease NL4-3 recombinant viruses display significantly lower
replication capacity than subtype B Gag-protease NL4-3 recombinant viruses. To
FIG 1 Contribution of Gag-protease to overall HIV-1 replication capacity. The graph shows a significant
positive correlation (Pearson’s correlation) between the replication capacities (RC) of HIV-1 subtype C
isolated from patients and the corresponding NL4-3 recombinant viruses encoding Gag-protease derived
from the same patients. Replication capacity was assayed in GXR cells using flow cytometry and
normalized to the growth of the wild-type NL4-3 virus (replication capacity of 100%).
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investigate Gag-protease-mediated differences in replication capacity between HIV-1
subtypes, the in vitro replication capacities of 803 and 406 NL4-3 recombinant viruses
encoding Gag-protease from antiretroviral therapy-naive patients chronically infected
with HIV-1 subtype B (41) and subtype C (39), respectively, were compared. Subtype B
Gag-protease NL4-3 recombinant viruses exhibited significantly higher replication ca-
pacities (mean  1; standard deviation [SD]  0.15) than the subtype C Gag-protease
recombinant viruses (mean  0.62; SD  0.1) (Mann-Whitney U test; P  0.0001)
(Fig. 2A). To exclude the possibility that this difference was due to interlaboratory
variation (the subtype B and C recombinants were generated and assayed in different
laboratories), a representative subset of the subtype B Gag-protease NL4-3 recombi-
nants (n  25) were generated and assayed in the same laboratory as the subtype C
Gag-protease NL4-3 recombinants, with consistent results (Mann-Whitney U test; P 
0.0001) (Fig. 2B). Since viral replication capacity may be related to stage of disease (41,
43), a subset (n  25) of HIV-1 subtype C-infected patients were matched with a subset
(n  25) of subtype B-infected patients in terms of CD4 T cell counts and viral loads
(medians [interquartile ranges], 140 [60 to 320] cells/mm3 and 5.4 [5.2 to 5.6] log10
copies/ml for subtype B, and 137 [76 to 341] cells/mm3 and 5.3 [4.9 to 5.7] log10
copies/ml for subtype C), and the analysis was repeated. The replication capacities of
this subtype C subset (mean  0.65; SD  0.08) were still significantly lower than the
replication capacities of the subtype B Gag-protease NL4-3 recombinants (mean 0.95;
SD  0.13) (Mann-Whitney U-test; P  0.0001) (Fig. 2C). These results suggest that
subtype C Gag-protease is less functional than that of subtype B and further suggest
that subtype-specific differences in this region could contribute to the lower in vitro
replication capacity reported for HIV-1 subtype C isolates than for those of subtype B
(20).
Subtype C consensus Gag pZM246-F10 recombinant virus displays lower rep-
lication capacity than NL4-3 Gag pZM246-F10 recombinant virus. It is conceivable
that the engineering of subtype C Gag-protease into the subtype B NL4-3 viral
backbone may have disrupted the natural context, resulting in suboptimal replication
of the subtype C Gag-protease NL4-3 recombinant viruses. However, two observations
argue against this possibility. First, greater similarity of the subtype C Gag sequences to
the subtype B consensus did not correlate with higher subtype C Gag-protease NL4-3
recombinant virus replication capacity (39). Second, we engineered the subtype C
consensus and subtype B NL4-3 Gag sequences into a subtype C viral backbone,
pZM246-F10, and observed that the former replicated substantially slower than the
latter (Fig. 3). It should be noted that the replication of wild-type pZM246-F10 was very
poor in our experiments. This may be attributed to the several B*57/B*58:01-associated
mutations, previously reported to reduce replication, encoded by pZM246-F10 Gag
(44). Thus, the consensus C Gag was engineered into the pZM246-F10 backbone to
represent subtype C. Together, these results suggest that subtype C Gag-protease is
inherently less functional than subtype B Gag-protease.
Gag codons 483 and 484 are major determinants of subtype-specific replica-
tion capacity. We next investigated the genetic determinants of the functional differ-
ences between subtypes. Since previous studies showed no difference (or increased
efficiency) of subtype C compared to subtype B protease (30, 31), we hypothesized that
Gag largely mediates the differences observed. HIV gag encodes four posttranslation-
ally cleaved proteins: p17 (matrix), p24 (capsid), p7 (nucleocapsid), and p6. Given
previous data underscoring the structural Gag p24 protein as a key determinant of
HIV-1 replication capacity (45, 46), we initially compared the replication capacities of
HIV-1 wild-type NL4-3 and of NL4-3 encoding the consensus C Gag p24. However, we
observed that these viruses replicated similarly (Fig. 4), suggesting that the determi-
nants underlying the functional difference between subtype B and subtype C Gag-
proteases are outside p24. Codon function analysis of our subtype B and C Gag
sequences identified subtype-specific polymorphisms at codons 67 (matrix), 473 (p6),
and 483 (p6) that were strongly linked to altered viral replication capacities in our
previous studies (39, 41) (Table 1). Specifically, 67A is the consensus amino acid in
Kiguoya et al. Journal of Virology
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subtype C and is strongly associated with decreased replication capacity in subtype B
(41), where 67S is the consensus. In both subtypes B and C, 473P is associated with
increased replication capacity (39, 41), and the frequencies of this polymorphism are
39% and 1.7%, respectively, in the present subtype B- and subtype C-infected cohorts.
In subtype B, the consensus 483L is associated with significantly increased replication
capacity (41), while there is a deletion at positions 483 and 484 (indicated as 483/
484 here) in subtype C.
FIG 2 HIV-1 subtype B versus subtype C Gag-protease-mediated replication capacity. (A) Significant
differences between the replication capacities of NL4-3 recombinant viruses encoding subtype B (n 
803) (41) and subtype C (n  406) (39) Gag-proteases from patients chronically infected with HIV-1. (B)
A comparison of subtype B (n  25) and subtype C (n  406) Gag-protease-mediated replication
capacities performed in the same laboratory. (C) Significant differences between subtype B (n  25) and
subtype C (n  25) Gag-protease-mediated replication capacity remain when samples matched for viral
loads and CD4 counts are compared. Replication capacity was assayed in GXR cells using flow cytometry
and normalized to the growth of the wild-type NL4-3 virus (replication capacity of 100%). The Mann-
Whitney U test was used to test for significance, and lines represent the means.
Subtype Differences in Gag-Pro Replication Capacity Journal of Virology
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To further investigate whether these differences contribute to subtype differences in
Gag-protease-mediated replication capacity, subtype B- and C-specific Gag residues at
these sites were introduced into subtype C (SK-254) and subtype B (NL4-3) Gag-
proteases, respectively, by site-directed mutagenesis, and replication was measured in
an NL4-3 backbone. While alterations at residues 67 and 473 did not appreciably alter
replication capacity in either backbone (Fig. 5), deletion of Gag residues 483 and 484
from the subtype B Gag-protease decreased replication capacity to 81% of wild-type
levels (Fig. 5A). Correspondingly, insertion of the subtype B amino acids at these codons
into the subtype C Gag-protease increased replication capacity to 120% of wild-type
levels (Fig. 5B). We further confirmed that insertion of 483L/484Y into subtype C
increased replication capacity irrespective of the backbone subtype, by cloning the
SK-254 Gag into a subtype C MJ4 backbone and measuring the replication capacity in
GXR cells (an HIV-inducible GFP-reporter GXR T cell line) by detection of green fluo-
rescent protein (GFP)-positive cells as well as reverse transcriptase activity as previously
described (47). In the MJ4 backbone, insertion of 483L/484Y similarly increased repli-
cation capacity to 121% of wild-type levels (Fig. 5C). These results suggest that the
higher Gag-protease-mediated replication capacity of subtype B versus C sequences
may be mediated, at least in part, by the presence versus absence of Gag 483L/484Y in
these subtypes, respectively.
Gag-protease-mediated replication capacity differs significantly between sub-
types A, C, and D and intersubtype recombinants. The subtype B and C sequences
studied here were derived from different populations that differ substantially with
respect to sociodemographic, clinical, and host genetic characteristics (including
FIG 3 Replication kinetics of the subtype C consensus Gag pZM246-F10 and NL4-3 Gag pZM246-F10
recombinant viruses. Comparison of the replication kinetics of pZM246-F10 (subtype C) viral constructs
carrying the gag genes from subtype C consensus and NL4-3. The wild-type pZM246-F10 virus was
included as a control. The replication assay was carried out in activated pooled PBMCs from four donors
and monitored using p24 ELISA.
FIG 4 Replication kinetics of consensus C Gag p24 NL4-3 recombinant virus and NL4-3 wild-type virus.
The replication of NL4-3 encoding consensus C Gag p24 is similar to that of wild-type NL4-3. The
replication assay was carried out in GXR cells, and viral replication was monitored using flow cytometry
to measure GFP expression.
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HLA class I distributions, which are a major driver of Gag-protease-driven virus
replication capacity [39, 41, 48]), rendering it difficult to tease apart the relative
contributions of viral subtype versus other factors on HIV-1 disease progression
(49–51). We therefore sought to further explore intersubtype differences in Gag-
protease-driven replication capacity and their relationship to disease progression in
a single population in which multiple subtypes cocirculate in order to mitigate such
confounding factors.
The Gag-protease region was amplified and sequenced from 103 treatment-naive,
chronically infected individuals from a Kenyan cohort. Of these, 57 (55.4%) were
subtype A, 16 (15.5%) were subtype C, 13 (12.6%) were subtype D, and 17 (16.5%) were
intersubtype recombinants (Fig. 6). NL4-3 viruses encoding the patient-derived Gag-
proteases were constructed, and replication capacities were compared. Marked
differences in replication capacities were observed between subtypes (Fig. 7A).
Gag-protease intersubtype recombinants had the highest mean replication capac-
ity, 113% (P  0.001 compared to subtypes A, C and D), followed by subtype D with
a mean replication capacity of 94% (P  0.001 compared to subtype A, P  0.01
compared to subtype C), followed by subtypes C and A with mean replication
capacities of 78% and 69%, respectively, where 100% represents the replication
capacity of wild-type NL4-3. Although we were limited by sample size, we did not
observe significant differences in replication capacity between different intersub-
type recombinants or those with different common (n  5) patterns of recombi-
nation (data not shown).
CD4 T cell counts and viral loads were comparable across subtypes (Table 2),
suggesting that our observations are not driven by differences in clinical parameters.
Furthermore, subtype D is phylogenetically closer to subtype B (52, 53) than subtypes
A or C, raising the possibility that subtype D Gag-protease sequences would be
inherently more compatible in an NL4-3 backbone than subtypes A or C. Two lines
of evidence argue against such effects. First, there was no significant difference in
replication capacity between the subtype D-containing intersubtype recombinants
and nonsubtype D intersubtype recombinants (data not shown). Second, the
similarity of each Gag sequence to the consensus B Gag sequence did not correlate
with replication capacity (data not shown), supporting that the subtype B backbone
was not driving the differences in Gag-protease-driven replication capacity ob-
served between viruses encoding different subtypes of Gag-protease in the Kenyan
Majengo cohort.
Subtype differences in Gag-protease-mediated replication capacity are repro-
ducible across cohorts and geographical regions. To confirm that intersubtype
differences in viral replication capacity are consistent across cohorts and regions, we
generated and assessed the replication capacities of 30 Gag-protease recombinant
viruses (10 samples each from subtypes A and D and AD recombinants) from the
UARTO cohort in Uganda. To reduce confounding by clinical factors, selected samples
were matched for CD4 T cell counts and viral loads (medians [interquartile ranges],
171 [134.25 to 241.50] cells/mm3 and 5.2 [4.56 to 5.70] log10 copies/ml for subtype A,





Associations with RCB C
67 S A 67A with decreased RC in subtype B (P  0.0001) (41).
473 S A 473Pb with increased RC in subtypes B (P  0.0001) and
C (P  0.01) (39, 41).
483/484 L/Y /c 483L with increased RC in subtype B (P  0.0001) (41).
aRC, replication capacity.
b473P is more frequent in subtype B (39%) than subtype C (1.7%).
c/, deletion of residues.
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154 [119.25 to 199] cells/mm3 and 5.0 [4.69 to 5.64] log10 copies/ml for subtype D, and
147 [107 to 204.75] cells/mm3 and 5.0 [4.28 to 5.65] log10 copies/ml for AD recombi-
nants). Consistent with our previous observations, replication capacity differed mark-
edly between subtypes (Fig. 7B). AD recombinants had the greatest replication capac-
ity, 142% (P  0.01 compared to subtype A), followed by subtype D with a mean of
107% (P  0.05 compared to subtype A) and lastly subtype A with a mean of 76%,
where 100% represents the replication capacity of wild-type NL4-3.
FIG 5 Replication capacities of HIV-1 subtype B and C viruses encoding subtype-specific mutations in
Gag. (A) Replication capacities of subtype B NL4-3 wild-type virus and NL4-3 viruses encoding subtype
C-specific Gag residues 67S, 473A, and 483/484. (B) Replication capacities of NL4-3 recombinant
viruses encoding wild-type subtype C Gag derived from patient SK-254 and SK-254 Gag with introduced
subtype B-specific Gag residues 67S, 473P, and 483L/484Y. (C) Replication capacities of MJ4 recombinant
viruses encoding wild-type subtype C Gag derived from patient SK-254 and SK-254 Gag with introduced
subtype B-specific Gag residues 483L/484Y. Replication capacities were assayed in GXR cells using flow
cytometry and are expressed relative to the capacity of the respective wild-type virus, which represents
100% replication. Bars represent the means from at least 3 independent experiments, and error bars
represent standard deviations from the means.
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Subtype-specific differences in Gag-driven replication capacity are consistent
using a subtype C backbone. To more fully address the potential that subtype-specific
differences in replication capacity simply reflect incompatibility with the NL4-3 subtype
B backbone, additional experiments were performed using a pZM246-F10 subtype C
FIG 6 Gag-protease subtype composition of the Kenyan Majengo cohort. (A) Maximum likelihood phylogenetic tree shows clustering of patient-derived
Gag-protease gene sequences into distinct subtypes. Subtype reference A (A1, n  37; A2, n  20), C (n  16), and D (n  13) and intersubtype recombinant
(n  17) sequences are represented by black, red, purple, blue, and green, respectively. The scale bar indicates 2% nucleotide sequence divergence. (B)
Illustration of Gag-protease intersubtype recombinants. The subtypes A, C, and D are represented by red, purple, and blue, respectively. Numbering is according
to the HXB2 reference strain. Residues (150, 410, and 435) at which recombination breakpoints were common (observed 5 or more times) are highlighted in
bold.
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backbone. A total of 5 patients (one each for A, B, C, and D subtypes and one for AD
recombinants) for which their Gag-protease NL4-3 recombinant viruses represented the
average replication capacity for each subtype were selected for the generation of
patient-derived Gag pZM246-F10 recombinant viruses; the NL43 Gag-protease se-
FIG 7 Intersubtype comparison of Gag-protease-mediated replication capacity in East African cohorts. (A)
Significant differences in Gag-protease-mediated replication capacities of NL4-3 recombinant viruses
encoding patient-derived Gag-proteases of subtypes A, C, and D and intersubtype recombinants from a
Kenyan cohort. (B) Significant differences in replication capacities between subtypes are reproducible in
a Ugandan cohort. Replication capacity was assayed in GXR cells using flow cytometry and normalized
to the growth of the wild-type NL4-3 virus (replication capacity of 100%). Subtypes A, C, and D and
intersubtype recombinants are represented in red, purple, blue, and green, respectively. The bars and
whiskers represent the means and interquartile ranges, respectively. ANOVA (P value shown) with Tukey
post hoc tests was used to test for significant differences between subtypes. The number of asterisks
denotes the level of significance: *, P  0.05; **, P  0.01; ***, P  0.001.
TABLE 2 Characteristics of Majengo study subjects infected with HIV-1 subtypes A, C, and D and intersubtype recombinantsa
Characteristic Subtype A (n  57) Subtype C (n  16) Subtype D (n  13) Recombinants (n  17) P value
Age (yr) 35 (31–40) 37 (33–42) 31 (25–35) 35 (27–40) 0.39
CD4 count (cells/mm3) 421 (342–590) 376 (307–471) 427 (356–509) 358 (351–400) 0.14
Plasma HIV-1 RNA (log10 copies/ml) 4.20 (3.71–5.18) 4.04 (3.81–4.95) 5.00 (4.21–5.73) 5.23 (4.65–5.32) 0.16
aValues for subtypes and recombinants are medians, with interquartile ranges in parentheses. P values were calculated using the Kruskal-Wallis test.
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quence was also inserted into pZM246-F10 as the normalization control (Table 3). It
should be noted that wild-type pZM246-F10 was not included as a control, as it
encodes B*57/B*58:01-associated mutations and replicates poorly (Fig. 3). Two inde-
pendent attempts to generate the subtype A Gag pZM246-F10 recombinant virus
failed, consistent with this subtype having the lowest replication capacity, although
incompatibility with the subtype C backbone cannot be ruled out. Thus, conclusive data
regarding the position of subtype A in the replication hierarchy using the pZM246-F10
backbone could not be obtained. The pZM246-F10 recombinant viruses encoding the
other Gags of different subtypes were successfully generated; however, the virus
growth using this backbone was particularly slow, which is consistent with previous
reports of subtype C isolates having lower replication ability than other M group
subtypes (20) and reports of poor growth of subtype C isolates in monocyte-
macrophage cultures and T cell lines (54). A similar replication hierarchy of these viruses
was observed in both GXR cells (Table 3; C  D  AD recombinant  B) and peripheral
blood mononuclear cells (PBMCs) (Fig. 8; C  D  AD recombinant/B). Thus, Gag-
protease replication is broadly consistent in both pZM246-F10 and NL4-3 backbones,
viz., lower replication capacity of subtype C versus subtype B Gag-proteases and the
replication hierarchy of A  D  intersubtype Gag-protease recombinants observed in
East Africa. More data may be required to discriminate between Gag/Gag-protease-
driven replication capacities in subtypes A versus C and subtypes B versus intersubtype
recombinants.
TABLE 3 Replication capacities of recombinant viruses encoding patient-derived Gag/Gag-
proteases of different subtypes in GXR cells
Subtype of Gag/Gag-proteasea RC in NL4-3 backboneb RC in pZM246-F10 backbonec
A 0.66 NDd
B 0.99 1.05
B (NL4-3) 1 1
C 0.62 0.51
D 0.97 0.60
AD recombinant 1.08 0.90
aPatient-derived Gag proteins and Gag-proteases of different subtypes as well as the laboratory strain NL4-3.
bRCs of NL4-3 (subtype B) recombinant viruses encoding patient-derived Gag-proteases of different subtypes
were normalized to wild-type NL4-3.
cRCs of pZM246-F10 (subtype C) recombinant viruses encoding patient-derived Gags of different subtypes
were normalized to NL4-3 Gag pZM246-F10.
dND, not determined: two independent attempts to generate pZM246-F10 recombinant viruses encoding the
patient-derived A Gag failed, and thus RC could not be assessed.
FIG 8 Intersubtype comparison of Gag-driven replication capacity in PBMCs using the subtype C
pZM246-F10 backbone. Comparison of the replication kinetics of pZM246-F10 (subtype C) viral con-
structs carrying patient-derived gag genes of different subtypes as well as NL4-3 gag. The patients for
whom the derived Gag-protease NL4-3 recombinant viruses represented the average replication capacity
for each subtype were selected for generation of patient-derived Gag pZM246-F10 recombinant viruses.
Subtypes B, C, and D and intersubtype recombinants are represented in gray, purple, blue, and green,
respectively. The replication assay was carried out in activated pooled PBMCs from two donors and
monitored using p24 ELISA.
Subtype Differences in Gag-Pro Replication Capacity Journal of Virology
July 2017 Volume 91 Issue 13 e00253-17 jvi.asm.org 11
 o
n






Genetic correlates of Gag-protease-mediated replication capacity in East Af-
rica. (i) Overrepresentation of the 483L/484Y motif in intersubtype recombinant
sequences. The Gag 483L/484Y motif, which likely explains in part the higher replica-
tion of subtype B than C sequences, is present in the subtype D consensus sequence
but absent in the consensus A sequence (which has residues QDP instead of LY at this
position). Of interest, of the 14 recombinants in the Majengo cohort that featured a
subtype D component, 11 (79%) were subtype D at the 3= end of Gag (Fig. 6) (two-tailed
binomial test; P  0.057). Moreover, the 483L/484Y motif was present in 10 of the 17
recombinants (59%) compared to only 8 of the 86 (9%) pure subtype A, C, or D
sequences assessed (Fisher’s exact test; P  0.0001). Taken together, these results
suggest that the Gag 483L/484Y motif is overrepresented among intersubtype recom-
binants in East Africa, which may in turn contribute to the enhanced replication
capacity of these sequences.
(ii) Single-amino-acid variants associated with altered replication capacity. We
have previously identified single-amino-acid variants in subtype B and subtype C
Gag-proteases that are associated with altered replication capacity (39, 41). Although
we were limited by sample size, we performed an exploratory codon-by-codon analysis
in our subtype A sequences to identify Gag-protease residues associated with altered
replication capacity (our subtype D data set was not large enough to perform such an
analysis). In doing so, we identified six amino acids significantly (P  0.05 and q  0.2)
associated with reduced or increased replication capacity (Table 4). We next compared
the frequency of these residues in 400 subtype A and 400 subtype D sequences
retrieved from the Los Alamos HIV sequence database (http://www.hiv.lanl.gov). Four of
the six residues differed significantly in frequency between the subtypes. Of note, 107L
and 315N, both associated with reduced replication capacity, were significantly more
frequent in subtype A than in subtype D (8% versus 0% and 66% versus 57%,
respectively). However, these frequency differences are moderate, and therefore, while
it is possible that these differences contribute to the lower replication capacity of
subtype A sequences, further studies are required to investigate the genetic determi-
nants of Gag-protease functional differences between subtypes A, C, and D and
intersubtype recombinants.
DISCUSSION
There are striking differences in the spread and prevalence of different HIV-1
subtypes; however, the intrinsic biological properties that may contribute to these
differences are not completely known (2, 4). In this study, we compared the functions
of Gag-protease, which is essential for HIV-1 replication (42) and has previously been
correlated with disease progression (39, 41), in different subtypes in large well-
characterized cohorts. We demonstrate here that there are significant intersubtype
TABLE 4 Amino acids (observed 5 or more times) in Gag associated with altered Gag-
protease-mediated replication capacity in subtype A




P value q valueAA AA AA AA
75 I L 65 70 13 40 0.07 0.04
107 L I 64 69 9 43 0.007 0.03
125 S S 70 65 37 15 0.02 0.03
126 S S 69 62 47 8 0.01 0.03
315 N N 67 71 18 36 0.05 0.04
499 S S 70 62 48 6 0.03 0.04
aAccording to HXB2 numbering.
bAA, amino acid variant associated with differences in replication capacity.
cMedian replication capacity (expressed as a percentage of wild-type NL4-3) of viruses with (AA) and
without (AA) the amino acid variant.
dNumber of sequences with (AA) and without (AA) the amino acid variant. Amino acid totals vary, as
gaps in the alignment are considered missing data.
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differences in Gag-protease function: patient-derived subtype C Gag-protease recom-
binant viruses replicate significantly slower than their subtype B counterparts, and a
hierarchy of Gag-protease-driven replication capacity—subtypes A/C  D  intersub-
type recombinants—was observed in two independent East African cohorts.
The intersubtype differences in Gag-protease function are largely consistent with
those observed for the replication capacity of whole virus isolates in studies where
competition assays were performed in PBMCs for limited numbers of isolates of
different subtypes (19, 20, 27). In those studies, subtype C isolates from Africa were
shown to have lower replication capacity than other M group isolates, including those
of subtype A, while we show that subtype C Gag-protease-driven replication capacity
is significantly lower than that of subtypes B and D and intersubtype recombinants but
similar to or lower than that of subtype A (indicating that genetic determinants other
than Gag-protease may distinguish the replication capacities of subtype A and C
isolates). Using an ex vivo competition assay in PBMCs, Abraha et al. described a
replication capacity hierarchy of B  D  A  C (subtype A isolates replicated
significantly slower than subtype B isolates; however, more isolates are required to
confirm significant differences between each subtype) (20), which is consistent with our
finding that subtype A Gag-proteases were less functional than those of subtype D (and
by inference less functional than subtype B Gag-proteases, since they were on par with
subtype C Gag-proteases). Furthermore, intersubtype recombinant isolates have been
shown to outcompete isolates of their parental subtypes (25, 26), and we demonstrate
here that viruses encoding intersubtype recombinant Gag-protease have a greater
replication capacity than those with subtypes A, C, and D. These observations, taken
together with our finding that the replication capacities of subtype C whole virus
isolates correlated with that of recombinant viruses encoding the Gag-proteases de-
rived from these isolates, confirm that Gag-protease is a significant determinant of
overall viral replication capacity, in addition to Env (19) and protease-reverse transcrip-
tase (55), which have also been shown to correlate with whole-isolate replication
capacity. In further support of Gag as an important contributor to replication capacity,
a recent study described a strong correlation between the replication capacities of 6
subtype C full-length infectious molecular clones and MJ4 recombinant viruses encod-
ing their respective Gag proteins (56).
It is likely that Gag, rather than protease, is the major contributor to the results
observed here (at least for the comparison of subtypes B and C), since protease has
previously been shown to have similar activity in subtypes B and C (30) or greater
catalytic efficiency in subtype C than B (31), which is not consistent with the overall
lower replication capacity of subtype C isolates. Furthermore, the replication hierarchies
of NL4-3 recombinant viruses encoding Gag-protease of different subtypes and
pZM246-F10 recombinant viruses encoding Gag of different subtypes were consistent,
indicating that Gag and not protease was the main driver of these results. Consistent
with our observations for Gag, the Env (29) and reverse transcriptase (30) (which are
also significant determinants of overall replication capacity) as well as Nef proteins (36)
have been shown to have lower functionality in subtype C than in subtype B. In
contrast, protease (31), Vif (32), and LTR (34, 57) are more active in subtype C than in
other subtypes, which might reflect compensatory mechanisms for reduced function-
ality of other proteins, although the overall replication capacity of subtype C isolates
remains compromised relative to other subtypes.
The intersubtype differences in Gag-protease-driven replication capacity could in-
fluence the spread and consequently the prevalence of different subtypes. This could
occur through the influence of the disease progression rate, which then affects the
opportunity for transmission (17). Gag-protease function could significantly affect
disease progression rate: Gag-protease function reflects the overall replication capacity
of isolates, for which distinct differences have been shown between long-term non-
progressors and progressors, indicating that this parameter significantly influences the
rate of disease progression (28, 45, 58), and furthermore, Gag-protease- and Gag-driven
replication capacities have been independently correlated with markers of disease
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progression (38–41). Moreover, the hierarchy of Gag-protease-driven replication capac-
ity—subtypes A  D  intersubtype recombinants—that we observed in the East
African cohorts is overall consistent with intersubtype differences in the disease pro-
gression reported in this region: subtype A resulted in a slower disease progression
than subtype D in cohorts from Uganda (10, 11), Kenya (13), and Tanzania (12), and in
Uganda, intersubtype recombinants resulted in faster progression to AIDS/death than
subtype A and had a slightly higher hazard ratio for death than did subtype D (10) (yet
increased virulence of intersubtype recombinants was not observed in Tanzania [12]).
In addition, in Guinea-Bissau, infection with recombinant A3/02 was associated with
increased risk of AIDS or death compared with subtype A3 (14). There is also evidence
for reduced subtype C Gag-protease function relative to subtype B, corresponding with
slower disease progression in subtype C-infected individuals; in Brazil, where subtype
C cocirculates with subtypes B and F1 and intersubtype recombinants, subtype C was
associated with higher CD4 counts (18). However, there are conflicting reports of the
disease progression rate of subtype C relative to that of subtypes A and D (12, 15–17,
59). Nevertheless, overall, our data suggest that the lower Gag-protease-driven repli-
cation capacity of subtypes A and C (in addition to the lower Pol-driven replication
capacity for subtype A [35]) may contribute to slower disease progression in individuals
infected with these subtypes. The associated increased longevity is expected to result
in greater opportunity for transmission (17) and hence in an increased prevalence of
these subtypes. Accordingly, subtype C is the most prevalent subtype worldwide and
subtype A is the predominant subtype in East Africa (2, 3). Furthermore, reports indicate
that these subtypes are increasing in prevalence (2, 8, 9, 17).
Aside from the hypothesis that Gag-protease-mediated replication capacity influ-
ences a differential spread of subtypes through affecting disease progression, viral
replication capacity has been directly linked to transmissibility. Several studies on RNA
viruses have shown that genetic bottlenecks (such as occur during transmission) reduce
viral replication capacity (60–62). More recently, it was described that viruses transmit-
ted heterosexually did not have an enhanced viral replication capacity (63). Further-
more, we have observed in mother-to-child transmission pairs that recombinant viruses
encoding Gag-protease from the infants had significantly lower replication capacities
than those from their mothers (Vanessa L. Naidoo, Jaclyn K. Mann, Christie Noble, Emily
Adland, Jonathan M. Carlson, Jake Thomas, Chanson J. Brumme, Christina F.
Thobakgale-Tshabalala, Zabrina L. Brumme, Mark A. Brockman, Philip J. R. Goulder,
Thumbi Ndung’u, submitted for publication). Taken together, these data lead to the
hypothesis that HIV-1 variants with a lower viral replication capacity or lower Gag-
protease-mediated replication capacity may be more transmissible, and this may be a
factor underlying the differential spread of subtypes. Indeed, subtypes A and C, which
have the lowest Gag-protease-driven replication capacity in the present study, may
have increased transmissibility relative to other subtypes (21, 22, 24). The mechanism
underlying the potentially increased transmissibility of viruses with low replication
capacity remains unknown. We speculate that the mechanism may relate to the half-life
of productively infected cells in genital fluids that are transmitted. Free infectious
virions have a short half-life; however, transmitted productively infected cells may
continue to release virions after the sexual encounter (thus, productively infected cells
in the transmitted genital fluid would increase transmission risk as opposed to free
virions alone). A virus with a high replication capacity may result in a shortened half-life
of productively infected cells due to a higher budding rate, thereby paradoxically
decreasing transmission risk, while a virus with low replication capacity may result in a
longer half-life of productively infected cells and therefore increased transmission risk.
Another possible factor contributing to increased transmissibility of subtype C is the
low frequency of switch from CCR5-tropic virus to CXCR4-tropic virus relative to other
subtypes, resulting in subtype C having a larger proportion of viruses that use the CCR5
receptor (4), which is required for cell entry of the transmitted virus (64).
In this study, we investigated the genetic determinants of intersubtype differences
in Gag-protease-driven replication capacity. We observed that recombinant viruses
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encoding subtype B and subtype C Gag p24 did not differ in replication capacity,
indicating that the genetic determinants of differences in Gag-protease function were
outside this region. An investigation of residues that differed in frequency between
subtypes B and C and were also statistically linked to altered Gag-protease-mediated
replication capacities in our previous studies (39, 41) revealed that subtype-specific
differences at residues 483 and 484 in Gag p6 are a significant determinant of the
difference in Gag-protease function between subtypes B and C. Specifically, deletion of
these residues, which are not present in the vast majority of subtype C Gag sequences,
from subtype B Gag-protease reduced viral replication capacity, and correspondingly,
introduction of these residues (483L/484Y) into a subtype C Gag-protease increased
replication capacity. Interestingly, the 483L/484Y motif (consensus for subtypes B and
D) was present in 59% of the intersubtype recombinant Gag sequences yet present in
only 9% of the other Gag sequences in the Majengo cohort. The overrepresentation of
the 483L/484Y motif in the intersubtype recombinants suggests that it is advantageous
and may partially contribute to the enhanced replication capacity of these viruses.
Residues 483 and 484 are essential residues in a late domain for binding the Alix host
protein (65), which acts in concert with the primary budding factor Tsg101 to mediate
viral budding (66). Mutants with disrupted Alix binding have significantly reduced
particle production and infectivity, demonstrating an important role for Alix in
HIV-1 replication (66). Recently, it was shown that the subtype C Gag p6 cannot
bind Alix and that replacement of NL4-3 Gag p6 with subtype C Gag p6 reduced
viral replication, although this could not conclusively be attributed to the 483L/
484Y deletion (67). Here, we directly demonstrate that the 483L/484Y deletion,
present almost universally in subtype C sequences, reduces viral replication and is
likely a major contributor to the lower replication capacity of viruses encoding
subtype C Gag-proteases. It is also of interest that an unusual mutant with deletion
at residues 482 and 483, shown to disrupt Alix binding (68), was previously
associated with nonprogressive HIV-1 infection (69), indicating that the ability to
bind Alix may influence disease progression. Furthermore, it was recently described
that a PYxE insertion (at the same position as the LY motif) in some East African
subtype C isolates enhanced the replication capacity and virulence of these isolates
compared to subtype C isolates without the insertion (70).
The assay employed in this study has several limitations; namely, it does not take
into account interactions between different genes, the use of an NL4-3 backbone
resulted in mixing of subtypes, and a cell line rather than primary cells was used to
measure replication. Nevertheless, the assay yields results that correlate with the
replication capacity of whole virus isolates and consistently correlate with markers of
disease progression (38, 39, 41). Although we cannot conclusively rule out that the
NL4-3 backbone may have partially influenced differences in Gag-protease-driven
replication capacity between subtypes, the subtype-specific differences in Gag-driven
replication capacity using a subtype C backbone were consistent with subtype-specific
Gag-protease-driven replication capacity differences observed in the subtype B NL4-3
backbone.
In summary, we show that Gag-protease is an important determinant of viral
replication capacity and that it differs substantially in functionality between HIV-1
subtypes, with subtype C showing lower functionality than subtype B and a functional
hierarchy of subtypes (A/C  D  intersubtype recombinants) observed within East
African populations. Since previous studies suggest an important influence of Gag-
protease on disease progression, it is likely that the lower functionality of subtype A and
C Gag-proteases slows disease progression in individuals infected with these subtypes,
leading to a greater opportunity for transmission (as well as potential increased
transmissibility) and a consequently increased prevalence of these subtypes. Impor-
tantly, we demonstrate that the hierarchy of Gag-protease-driven replication capacity
in East Africa, where these subtypes cocirculate, is consistent with reported intersub-
type differences in disease progression in this population, supporting that Gag-
protease-driven replication capacity is a determinant of disease progression and dif-
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ferential spread of subtypes. Furthermore, our study sheds light on the genetic
determinants of intersubtype differences in Gag-protease-mediated replication capac-
ity, although studies to further investigate this are warranted. Future studies using
full-length infectious molecular clones and whole-genome sequencing in large cohorts
in which several subtypes cocirculate could further elucidate the biological determi-
nants of subtype differences in disease and spread.
MATERIALS AND METHODS
Study subjects. All study subjects were antiretroviral naive and chronically infected. For comparison
of subtypes B and C, 803 individuals from the British Columbia HAART (highly active antiretroviral
therapy) Observational Medical Evaluation and Research (BC HOMER) cohort (n  762) and Boston
chronic progressors cohort (n  41) (41) and 406 individuals from the South African Sinikithemba (SK)
cohort (39) were studied. To compare different subtypes in a population in which they cocirculate,
we studied 103 individuals from the Kenyan Majengo sex worker cohort (71) who were infected with
subtypes A (n  57), C (n  16), and D (n  13) and intersubtype recombinants (n  17). In addition,
we investigated the reproducibility of subtype differences in 30 individuals from the Ugandan
UARTO cohort (72) who were infected with subtypes A (n  10) and D (n  10) and AD recombinants
(n  10).
Specimens from the BC HOMER cohort comprised historic plasma samples that were anonymized
according to Research Ethics Board (REB)-approved procedures prior to study. Approval was granted by
the Research Ethics Board of Providence Health Care/University of British Columbia. Written informed
consent was obtained from all other study participants, and ethical approval was granted from the
following: Institutional Review Board at Massachusetts General Hospital (Boston chronic progressors
cohort), Biomedical Research Ethics Committee of the University of KwaZulu-Natal (Sinikithemba cohort),
Biomedical Research Ethics Committee of the University of KwaZulu-Natal and the Ethics Review
Committee of the Kenyatta National Hospital Ethics Review Board (Majengo cohort), and institutional
review boards at Mbarara University, Massachusetts General Hospital, and the University of California, San
Francisco (UARTO cohort).
Whole-virus isolation. For 16 subtype C-infected individuals from the SK cohort, HIV-1 was isolated
from peripheral blood mononuclear cells (PBMCs) as previously described (73). Briefly, patient PBMCs
were cocultured with prestimulated PBMCs from two anonymous HIV-1-negative donors, and the virus
concentration in the supernatants was monitored by p24 enzyme-linked immunosorbent assay (ELISA;
bioMérieux, Netherlands) every 3 days. Isolates were briefly cultured in a CEM-derived GFP reporter GXR
T cell line (CEM-GXR25, here abbreviated to GXR) (74) to generate high titer virus stocks.
Amplification and sequencing of Gag-protease. Gag-protease was amplified and sequenced as
described previously (39). Sequence data were aligned to HIV-1 subtype B reference strain HXB2
(GenBank accession number K03455), and insertions with respect to HXB2 were stripped out. HIV-1
subtype was confirmed using the REGA subtyping tool (75). A maximum likelihood phylogenetic tree was
drawn using PhyML, available at http://www.hiv.lanl.gov (76).
Generation of Gag-protease NL4-3 recombinant viruses. Gag-protease NL4-3 recombinant viruses
were constructed for all study subjects as described previously (39, 41, 77). Briefly, recombinant viruses
encoding patient-derived Gag-protease were generated by electroporation of an HIV-inducible GFP-reporter
GXR T cell line (GXR) with plasma-derived Gag-protease PCR products (amplified with primers complementary
to NL4-3) and linearized Gag-protease-deleted HIV-1 subtype B NL4-3 plasmid. Protease was included
together with Gag to maintain the important interaction between these proteins for each virus.
Generation of consensus C Gag pZM246-F10 and NL4-3 Gag pZM246-F10 recombinant viruses.
The pZM246-F10 HIV-1 subtype C infectious molecular clone, donated by Beatrice Hahn, was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH. The 2004 subtype C consensus Gag
sequence (available at http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html) was synthe-
sized (Integrated DNA Technologies) and cloned into pZM246-F10, using BssHII and XhoI restriction
enzymes as previously described (44). The NL4-3 Gag sequence was similarly cloned into pZM246_F10. Virus
stocks were generated by transfection of HEK293T cells (obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH, from Andrew Rice [78]) with 7.5 g of plasmid DNA, followed by harvesting of
supernatants after 72 h (44). The capsid concentration of the viral stocks was quantified by p24 ELISA.
Generation of consensus C Gag p24 NL4-3 recombinant virus. The consensus C Gag p24 NL4-3
recombinant virus was constructed as previously described (44). Briefly, the consensus C Gag p24 was
amplified using 100-bp-long primers matching the NL4-3 sequence upstream and downstream of p24,
and the virus stock was generated by electroporation of GXR cells with the amplicon as well as gag
p24-deleted NL4-3 plasmid.
Generation of pZM246-F10 (subtype C) recombinant viruses encoding patient-derived Gags of
different subtypes. Gag pZM246-F10 recombinant viruses were constructed using methods similar to
that described above. A total of 5 patients (one each for A, B, C, and D subtypes and one for AD
recombinants) for which their Gag-protease NL4-3 recombinant viruses represented the average repli-
cation capacity for each subtype were selected for generation of patient-derived Gag pZM246-F10
recombinant viruses. In addition, the NL43 Gag-protease sequence was also inserted into pZM246-F10.
Briefly, recombinant viruses were generated by electroporation of GXR cells with patient-derived gag PCR
products (amplified with primers complementary to pZM246-F10) and pZM246-F10 that was linearized
by digestion with BssHII and XhoI enzymes.
Kiguoya et al. Journal of Virology
July 2017 Volume 91 Issue 13 e00253-17 jvi.asm.org 16
 o
n






Generation of mutant viruses. A QuikChange II XL site-directed mutagenesis kit (Stratagene, La
Jolla, CA) and custom-designed mutagenic primers were used to introduce subtype C-specific residues
67A, 473A, and 483/484 into the subtype B NL4-3 plasmid. Similarly, subtype B-specific residues 67S,
473P, and 483L/484Y were introduced into a patient-derived subtype C Gag-protease sequence (SK-254;
GenBank accession number HM593258) of high similarity (96.4% amino acid similarity) to the consensus
subtype C Gag-protease sequence. Mutant NL4-3 viruses were generated as described previously (47) via
electroporation of GXR cells with 10 g of mutated NL4-3 plasmids. Mutant SK-254 Gag-protease NL4-3
viruses were generated by amplification of mutated SK-254 Gag-protease followed by transfection of
GXR cells with PCR product and Gag-protease-deleted NL4-3 plasmid (39).
Replication capacity measurement. The replication capacities of whole virus isolates and recom-
binant and mutant viruses were assayed in the GXR cell line by flow cytometry as described previously
(39). Briefly, virus titers were first determined by infecting GXR cells with the virus stocks and measuring
GFP expression after 2 days. The titer data were used to calculate the virus volume required to obtain
a multiplicity of infection (MOI) of 0.003 on day 2 of the replication capacity assay. Following infection
at an MOI of 0.003, GFP expression was measured daily for a week. Replication capacity was defined as
the slope of increase in the percentage of infected cells from days 3 to 6 postinfection, and results were
normalized to the growth of the relevant control (NL4-3 or SK-254 Gag-protease NL4-3 or NL4-3 Gag
pZM246-F10) assayed in parallel. Replication capacities were assayed at least in duplicate independently,
and results were averaged.
The replication capacities of consensus C Gag pZM246-F10 and NL4-3 Gag pZM246-F10 as well as of
pZM246-F10 recombinant viruses encoding patient-derived Gags of different subtypes were assayed in
prestimulated PBMCs pooled from at least 2 healthy HIV-negative donors by infection of 0.5 106 to 1
106 PBMCs with 20 ng p24 as previously described (44); here, p24 ELISA was used to monitor viral
replication every 2 to 3 days postinfection, up to a maximum of 21 days.
Data analysis. Pearson’s (for normally distributed variables) or Spearman’s (for nonnormally distrib-
uted variables) correlation was used to assess the relationship between continuous variables. A com-
parison of replication capacities between subtypes B and C was performed using the Mann-Whitney U
test, while analysis of variance (ANOVA) with Tukey’s posttests was used to compare replication
capacities between multiple subtypes in the East African cohorts. Clinical characteristics were compared
between patient groups infected with different subtypes using the Kruskal-Wallis test. An exploratory
codon-by-codon analysis was performed to identify specific amino acid variants that were significantly
associated with altered replication capacity in subtype A. Frequencies of amino acid variants of interest
were compared between subtypes using a chi-square test computer software (K. J. Preacher, Calculation
for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and
independence [http://quantpsy.org]). The significance cutoff for all statistical analyses was a P value
of 0.05. For the codon-by-codon analysis, multiple comparisons were addressed using q values, the P
value analogue of the false-discovery rate (79). Here, associations with P values of 0.05 and q values
of 0.2 were considered significant.
Accession number(s). Sequences from the Sinikithemba cohort and HOMER cohort were previously
deposited in GenBank (39, 41, 48, 80). The Gag-protease sequences from the Majengo and UARTO
cohorts are available in the GenBank database under accession numbers KX233975 to KX234077
(Majengo cohort) and KX377087 to KX377116 (UARTO cohort).
ACKNOWLEDGMENTS
We thank Richard Harrigan from the BC Centre for Excellence in HIV/AIDS and David
Bangsberg from the Ragon Institute of MGH, MIT and Harvard University for access to
samples and their support of the study. We also acknowledge Erasha Rajkoomar and
Doty Achieng’ Ojwach for technical assistance.
M.W.K., J.K.M., and D.C. received pilot grants from the Canada-Sub Saharan Africa
(CANSSA) HIV/AIDS Network through funding provided by the Global Health Research
Initiative (GHRI), itself a collaborative research funding partnership of the Canadian
Institutes for Health Research (CIHR), the Canadian International Development Agency
(CIDA), and the International Development Research Centre (IDRC). M.W.K. was partially
funded by a doctoral award program of the CIHR to strengthen sub-Saharan Africa
leadership in HIV prevention research. This research was further funded by grants from
the South African Department of Science and Technology through the National Re-
search Foundation, the Victor Daitz Foundation, and the Howard Hughes Medical
Institute to T.N. J.N.M. was supported by the National Institutes of Health (R01
MH054907, UM1 CA181255, and P30 AI027763). Generation of the subtype B recom-
binant viruses was funded by a grant from the Canadian Institutes for Health Research
(MOP-93536 to M.A.B. and Z.L.B.). Z.L.B. is supported by a scholar award from the
Michael Smith Foundation for Health Research (MSFHR). M.A.B. holds a Canada Re-
search Chair in Viral Pathogenesis and Immunity. This work was also partially supported
through the DELTAS Africa Initiative (grant DEL-15-006). The DELTAS Africa Initiative is
an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for
Subtype Differences in Gag-Pro Replication Capacity Journal of Virology
July 2017 Volume 91 Issue 13 e00253-17 jvi.asm.org 17
 o
n






Accelerating Excellence in Science in Africa (AESA) and is supported by the New
Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD
Agency) with funding from the Wellcome Trust (grant 107752/Z/15/Z) and the UK
government. The views expressed in this publication are those of the author(s) and not
necessarily those of the AAS, NEPAD Agency, Wellcome Trust, or UK government. The
funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
REFERENCES
1. Sharp PM, Hahn BH. 2008. Prehistory of HIV-1. Nature 455:605–606.
https://doi.org/10.1038/455605a.
2. Tebit DM, Arts EJ. 2011. Tracking a century of global expansion and
evolution of HIV to drive understanding and to combat disease. Lancet
Infect Dis 11:45–56. https://doi.org/10.1016/S1473-3099(10)70186-9.
3. Hemelaar J. 2012. The origin and diversity of the HIV-1 pandemic. Trends
Mol Med 18:182–192. https://doi.org/10.1016/j.molmed.2011.12.001.
4. Hemelaar J. 2013. Implications of HIV diversity for the HIV-1 pandemic.
J Infect 66:391–400. https://doi.org/10.1016/j.jinf.2012.10.026.
5. Los Alamos National Laboratory. HIV sequence database. https://
www.hiv.lanl.gov/content/sequence/HIV/mainpage.html. Accessed 7
April 2014.
6. Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for
HIV Isolation and Characterisation. 2011. Global trends in molecular
epidemiology of HIV-1 during 2000-2007. AIDS 25:679–689. https://doi
.org/10.1097/QAD.0b013e328342ff93.
7. UNAIDS. Fact sheet 2015. http://aidsinfo.unaids.org/. Accessed 19 Janu-
ary 2016.
8. Gräf T, Pinto AR. 2013. The increasing prevalence of HIV-1 subtype C in
Southern Brazil and its dispersion through the continent. Virology 435:
170–178. https://doi.org/10.1016/j.virol.2012.08.048.
9. Conroy SA, Laeyendecker O, Redd AD, Collinson-Streng A, Kong X,
Makumbi F, Lutalo T, Sewankambo N, Kiwanuka N, Gray RH, Wawer MJ,
Serwadda D, Quinn TC, Rakai Health Sciences Program. 2010. Changes in
the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda
between 1994 and 2002. AIDS Res Hum Retroviruses 26:1087–1091.
https://doi.org/10.1089/aid.2010.0054.
10. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F,
Eller LA, Eller M, Makumbi F, Birx D, Wabwire-Mangen F, Serwadda D,
Sewankambo NK, Quinn TC, Wawer M, Gray R. 2008. Effect of human
immunodeficiency virus type 1 (HIV-1) subtype on disease progression
in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis
197:707–713. https://doi.org/10.1086/527416.
11. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J,
Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J. 2002. Effect
of human immunodeficiency virus (HIV) type 1 envelope subtypes A and
D on disease progression in a large cohort of HIV-1-positive persons in
Uganda. J Infect Dis 185:1244–1250. https://doi.org/10.1086/340130.
12. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi
W, Hunter D. 2006. Different rates of disease progression of HIV type 1
infection in Tanzania based on infecting subtype. Clin Infect Dis 42:
843–852. https://doi.org/10.1086/499952.
13. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L,
Mandaliya K, Jaoko W, Overbaugh J. 2007. HIV-1 subtype D infection is
associated with faster disease progression than subtype A in spite of
similar plasma HIV-1 loads. J Infect Dis 195:1177–1180. https://doi.org/
10.1086/512682.
14. Palm AA, Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Biague A, da Silva
ZJ, Jansson M, Norrgren H, Medstrand P. 2014. Faster progression to
AIDS and AIDS-related death among seroincident individuals infected
with recombinant HIV-1 A3/CRF02_AG compared with sub-subtype A3.
J Infect Dis 209:721–728. https://doi.org/10.1093/infdis/jit416.
15. Easterbrook PJ, Smith M, Mullen J, O’Shea S, Chrystie I, de Ruiter A, Tatt
ID, Geretti AM, Zuckerman M. 2010. Impact of HIV-1 viral subtype on
disease progression and response to antiretroviral therapy. J Int AIDS
Soc 13:4. https://doi.org/10.1186/1758-2652-13-4.
16. Neilson JR, John GC, Carr JK, Lewis P, Kreiss JK, Jackson S, Nduati RW,
Mbori-Ngacha D, Panteleeff DD, Bodrug S, Giachetti C, Bott MA, Rich-
ardson BA, Bwayo J, Ndinya-Achola J, Overbaugh J. 1999. Subtypes of
human immunodeficiency virus type 1 and disease stage among women
in Nairobi, Kenya. J Virol 73:4393–4403.
17. Ariën KK, Vanham G, Arts EJ. 2007. Is HIV-1 evolving to a less virulent
form in humans? Nat Rev Microbiol 5:141–151. https://doi.org/10.1038/
nrmicro1594.
18. Silveira J, Santos AF, Martínez AM, Góes LR, Mendoza-Sassi R, Muniz CP,
Tupinambás U, Soares MA, Greco DB. 2012. Heterosexual transmission of
human immunodeficiency virus type 1 subtype C in southern Brazil. J
Clin Virol 54:36–41. https://doi.org/10.1016/j.jcv.2012.01.017.
19. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME,
Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA,
Kawamura T, Blauvelt A, Arts EJ. 2003. Comparing the ex vivo fitness of
CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes
B and C. J Virol 77:1021–1038. https://doi.org/10.1128/JVI.77.2.1021
-1038.2003.
20. Abraha A, Nankya IL, Gibson R, Demers K, Tebit DM, Johnston E, Kat-
zenstein D, Siddiqui A, Herrera C, Fischetti L, Shattock RJ, Arts EJ. 2009.
CCR5- and CXCR4-tropic subtype C HIV-1 isolates have a lower level of
pathogenic fitness than the other dominant group M subtypes: impli-
cations for the epidemic. J Virol 83:5592–5605. https://doi.org/10.1128/
JVI.02051-08.
21. Renjifo B, Gilbert P, Chaplin B, Msamanga G, Mwakagile D, Fawzi W,
Essex M, Tanzanian Vitamin and HIV Study Group. 2004. Preferential
in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype
A or D. AIDS 18:1629–1636. https://doi.org/10.1097/01.aids.0000131392
.68597.34.
22. John-Stewart GC, Nduati RW, Rousseau CM, Mbori-Ngacha DA, Richard-
son BA, Rainwater S, Panteleeff DD, Overbaugh J. 2005. Subtype C is
associated with increased vaginal shedding of HIV-1. J Infect Dis 192:
492–496. https://doi.org/10.1086/431514.
23. Rodriguez MA, Ding M, Ratner D, Chen Y, Tripathy SP, Kulkarni SS,
Chatterjee R, Tarwater PM, Gupta P. 2009. High replication fitness and
transmission efficiency of HIV-1 subtype C from India: implications for
subtype C predominance. Virology 385:416–424. https://doi.org/10
.1016/j.virol.2008.12.025.
24. Kiwanuka N, Laeyendecker O, Quinn TC, Wawer MJ, Shepherd J, Robb M,
Kigozi G, Kagaayi J, Serwadda D, Makumbi FE, Reynolds SJ, Gray RH.
2009. HIV-1 subtypes and differences in heterosexual HIV transmission
among HIV-discordant couples in Rakai, Uganda. AIDS 23:2479–2484.
https://doi.org/10.1097/QAD.0b013e328330cc08.
25. Konings FA, Burda ST, Urbanski MM, Zhong P, Nadas A, Nyambi PN.
2006. Human immunodeficiency virus type 1 (HIV-1) circulating recom-
binant form 02_AG (CRF02_AG) has a higher in vitro replicative capacity
than its parental subtypes A and G. J Med Virol 78:523–534. https://doi
.org/10.1002/jmv.20572.
26. Njai HF, Gali Y, Vanham G, Clybergh C, Jennes W, Vidal N, Butel C, Mpoudi-
Ngolle E, Peeters M, Ariën KK. 2006. The predominance of human immu-
nodeficiency virus type 1 (HIV-1) circulating recombinant form 02
(CRF02_AG) in West Central Africa may be related to its replicative fitness.
Retrovirology 3:40. https://doi.org/10.1186/1742-4690-3-40.
27. Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ.
2005. The replicative fitness of primary human immunodeficiency virus
type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol
79:8979–8990. https://doi.org/10.1128/JVI.79.14.8979-8990.2005.
28. Quiñones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham
G, van der Groen G, Colebunders RL, Arts EJ. 2000. A dual infection/
competition assay shows a correlation between ex vivo human immu-
nodeficiency virus type 1 fitness and disease progression. J Virol 74:
9222–9233. https://doi.org/10.1128/JVI.74.19.9222-9233.2000.
29. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD,
Arts EJ. 2005. Differences in the fitness of two diverse wild-type human
immunodeficiency virus type 1 isolates are related to the efficiency of
Kiguoya et al. Journal of Virology
July 2017 Volume 91 Issue 13 e00253-17 jvi.asm.org 18
 o
n






cell binding and entry. J Virol 79:7121–7134. https://doi.org/10.1128/JVI
.79.11.7121-7134.2005.
30. Iordanskiy S, Waltke M, Feng Y, Wood C. 2010. Subtype-associated
differences in HIV-1 reverse transcription affect viral replication. Retro-
virology 7:85. https://doi.org/10.1186/1742-4690-7-85.
31. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. 2001. Catalytic effi-
ciency and vitality of HIV-1 proteases from African viral subtypes. Proc
Natl Acad Sci U S A 98:6062–6067. https://doi.org/10.1073/pnas
.111152698.
32. Iwabu Y, Kinomoto M, Tatsumi M, Fujita H, Shimura M, Tanaka Y, Ishizaka Y,
Nolan D, Mallal S, Sata T, Tokunaga K. 2010. Differential anti-APOBEC3G
activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem
285:35350–35358. https://doi.org/10.1074/jbc.M110.173286.
33. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K,
Berkhout B. 2000. Functional differences between the long terminal
repeat transcriptional promoters of human immunodeficiency virus type
1 subtypes A through G. J Virol 74:3740–3751. https://doi.org/10.1128/
JVI.74.8.3740-3751.2000.
34. Naghavi MH, Schwartz S, Sönnerborg A, Vahlne A. 1999. Long terminal
repeat promoter/enhancer activity of different subtypes of HIV type 1.
AIDS Res Hum Retroviruses 15:1293–1303. https://doi.org/10.1089/
088922299310197.
35. Ng OT, Laeyendecker O, Redd AD, Munshaw S, Grabowski MK, Paquet
AC, Evans MC, Haddad M, Huang W, Robb ML, Reynolds SJ, Gray RH,
Wawer MJ, Serwadda D, Eshleman SH, Quinn TC. 2014. HIV type 1
polymerase gene polymorphisms are associated with phenotypic differ-
ences in replication capacity and disease progression. J Infect Dis 209:
66–73. https://doi.org/10.1093/infdis/jit425.
36. Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, Mwimanzi P,
Omarjee S, Martin E, Lee GQ, Baraki B, Danroth R, McCloskey R, Muzoora
C, Bangsberg DR, Hunt PW, Goulder PJ, Walker BD, Harrigan PR, Martin
JN, Ndung’u T, Brockman MA, Brumme ZL. 2013. Ability of HIV-1 Nef to
downregulate CD4 and HLA class I differs among viral subtypes. Retro-
virology 10:100. https://doi.org/10.1186/1742-4690-10-100.
37. Mann JK, Chopera D, Omarjee S, Kuang XT, Le AQ, Anmole G, Danroth R,
Mwimanzi P, Reddy T, Carlson J, Radebe M, Goulder PJ, Walker BD,
Abdool Karim S, Novitsky V, Williamson C, Brockman MA, Brumme ZL,
Ndung’u T. 2014. Nef-mediated down-regulation of CD4 and HLA class
I in HIV-1 subtype C infection: association with disease progression and
influence of immune pressure. Virology 468-470C:214–225. https://doi
.org/10.1016/j.virol.2014.1008.1009.
38. Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson
JM, Heckerman D, Wang B, Losina E, Leshwedi M, van der Stok M,
Maphumulo L, Mkhwanazi N, Chonco F, Goulder PJ, Essex M, Walker BD,
Ndung’u T. 2011. Influence of Gag-protease-mediated replication capac-
ity on disease progression in individuals recently infected with HIV-1
subtype C. J Virol 85:3996–4006. https://doi.org/10.1128/JVI.02520-10.
39. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ,
Wang B, Losina E, Miura T, Chonco F, van der Stok M, Mncube Z, Bishop
K, Goulder PJR, Walker BD, Brockman MA, Ndung’u T. 2010. Gag-
protease-mediated replication capacity in HIV-1 subtype C chronic
infection: associations with HLA type and clinical parameters. J Virol
84:10820–10831. https://doi.org/10.1128/JVI.01084-10.
40. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, Prentice
HA, Yue L, Vishwanathan SA, Kilembe W, Goepfert P, Price MA, Gilmour
J, Mulenga J, Farmer P, Derdeyn CA, Tang J, Heckerman D, Kaslow RA,
Allen SA, Hunter E. 2012. Role of transmitted Gag CTL polymorphisms in
defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog
8(11):e1003041. https://doi.org/10.1371/journal.ppat.1003041.
41. Brockman M, Brumme Z, Brumme C, Miura T, Sela J, Rosato P, Kadie C,
Carlson J, Markle T, Streeck H, Kelleher A, Markowitz M, Jessen H,
Rosenberg E, Altfeld M, Harrigan P, Heckerman D, Walker B, Allen T.
2010. Early selection in Gag by protective HLA alleles contributes to
reduced HIV-1 replication capacity that may be largely compensated for
in chronic infection. J Virol 84:11937–11949. https://doi.org/10.1128/JVI
.01086-10.
42. Freed EO, Martin MA. 2007. HIVs and their replication, p 2107–2185. In
Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B,
Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins,
Philadelphia, PA.
43. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW,
Toossi Z, Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ. 2005.
Changes in human immunodeficiency virus type 1 fitness and genetic
diversity during disease progression. J Virol 79:9006–9018. https://doi
.org/10.1128/JVI.79.14.9006-9018.2005.
44. Chopera DR, Cotton LA, Zawaira A, Mann JK, Ngandu NK, Ntale R,
Carlson JM, Mlisana K, Woodman Z, de Assis Rosa D, Martin E, Miura T,
Pereyra F, Walker BD, Gray CM, Martin DP, Ndung’u T, Brockman MA,
Karim SA, Brumme ZL, Williamson C, the CAPRISA 002 Study Team. 2012.
Intersubtype differences in the effect of a rare p24 Gag mutation on
HIV-1 replicative fitness. J Virol 86:13423–13433. https://doi.org/10.1128/
JVI.02171-12.
45. Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G,
Ndung’u T, Walker BD, Goulder P. 2010. Replicative capacity of human
immunodeficiency virus type 1 transmitted from mother to child is
associated with pediatric HIV-1 disease progression rate. J Virol 84:
492–502. https://doi.org/10.1128/JVI.01743-09.
46. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J,
Farmer P, Ndung’u T, Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow
R, Mulenga J, Allen S, Goulder PJR, Hunter E. 2009. Evolution of HLA-
B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and
their transmission recipients. J Exp Med 206:909–919. https://doi.org/10
.1084/jem.20081984.
47. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, Goulder PJR,
Brockman MA, Hunter E, Ndung’u T. 2012. Impact of HLA-B*81-
associated mutations in HIV-1 Gag on viral replication capacity. J Virol
86:3193–3199. https://doi.org/10.1128/JVI.06682-11.
48. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, Trocha A,
Block BL, Schneidewind A, Allen TM, Heckerman D, Walker BD. 2009.
HLA-associated alterations in replication capacity of chimeric NL4-3
viruses carrying gag-protease from elite controllers of human immuno-
deficiency virus type 1. J Virol 83:140–149. https://doi.org/10.1128/JVI
.01471-08.
49. Serwadda D, Wawer MJ, Musgrave SD, Sewankambo NK, Kaplan JE, Gray
RH. 1992. HIV risk factors in three geographic strata of rural Rakai District,
Uganda. AIDS 6:983–989. https://doi.org/10.1097/00002030-199209000
-00012.
50. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang
K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easter-
brook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith
JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ,
Haynes BF, Telenti A, Goldstein DB. 2007. A whole-genome association
study of major determinants for host control of HIV-1. Science 317:
944–947. https://doi.org/10.1126/science.1143767.
51. Weiss HA, Quigley MA, Hayes RJ. 2000. Male circumcision and risk of HIV
infection in sub-Saharan Africa: a systematic review and meta-analysis.
AIDS 14:2361–2370. https://doi.org/10.1097/00002030-200010200
-00018.
52. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD. 1998. An
African HIV-1 sequence from 1959 and implications for the origin of the
epidemic. Nature 391:594–597. https://doi.org/10.1038/35400.
53. Robertson D, Anderson J, Bradac J, Carr J, Foley B, Funkhouser R, Gao F,
Hahn B, Kalish M, Kuiken C. 2000. HIV-1 nomenclature proposal. Science
288:55–55. https://doi.org/10.1126/science.288.5463.55d.
54. Björndal A, Sönnerborg A, Tscherning C, Albert J, Fenyö EM. 1999.
Phenotypic characteristics of human immunodeficiency virus type 1
subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retrovi-
ruses 15:647–653. https://doi.org/10.1089/088922299310944.
55. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. 2003.
Relationship between in vitro human immunodeficiency virus type 1
replication rate and virus load in plasma. J Virol 77:12105–12112. https://
doi.org/10.1128/JVI.77.22.12105-12112.2003.
56. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, Kopy-
cinski J, Deymier MJ, Vanderford TH, Nganou-Makamdop K, Ende Z,
Brooks K, Tang J, Yu T, Lakhi S, Kilembe W, Silvestri G, Douek D, Goepfert
PA, Price MA, Allen SA, Paiardini M, Altfeld M, Gilmour J, Hunter E. 2015.
Replicative fitness of transmitted HIV-1 drives acute immune activation,
proviral load in memory CD4 T cells, and disease progression. Proc Natl
Acad Sci U S A 112:E1480 –E1489. https://doi.org/10.1073/pnas
.1421607112.
57. Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, Murali RV,
Mukthey AB, Bhatt R, Chatterjee S, Rajan RE, Cheedarla N, Yadavalli VS,
Mahadevan A, Shankar SK, Rajagopalan N, Shet A, Saravanan S,
Balakrishnan P, Solomon S, Vajpayee M, Satish KS, Kundu TK, Jeang KT,
Ranga U. 2012. Multiple NF-B sites in HIV-1 subtype C long terminal
repeat confer superior magnitude of transcription and thereby the
Subtype Differences in Gag-Pro Replication Capacity Journal of Virology
July 2017 Volume 91 Issue 13 e00253-17 jvi.asm.org 19
 o
n






enhanced viral predominance. J Biol Chem 287:44714–44735. https://
doi.org/10.1074/jbc.M112.397158.
58. Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H. 1998. In vitro
replication kinetics of human immunodeficiency virus type 1 (HIV-1)
variants in relation to virus load in long-term survivors of HIV-1 infection.
J Infect Dis 177:600–610. https://doi.org/10.1086/514219.
59. Amornkul PN, Karita E, Kamali A, Rida WN, Sanders EJ, Lakhi S, Price MA,
Kilembe W, Cormier E, Anzala O, Latka MH, Bekker LG, Allen SA, Gilmour J,
Fast PE, IAVI Africa HIV Prevention Partnership. 2013. Disease progression by
infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.
AIDS 27:2775–2786. https://doi.org/10.1097/QAD.0000000000000012.
60. Bergstrom CT, McElhany P, Real LA. 1999. Transmission bottlenecks as
determinants of virulence in rapidly evolving pathogens. Proc Natl Acad
Sci U S A 96:5095–5100. https://doi.org/10.1073/pnas.96.9.5095.
61. Lazaro E, Escarmis C, Perez-Mercader J, Manrubia SC, Domingo E. 2003.
Resistance of virus to extinction on bottleneck passages: study of a
decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci
U S A 100:10830–10835. https://doi.org/10.1073/pnas.1332668100.
62. Elena SF, Gonzalez-Candelas F, Novella IS, Duarte EA, Clarke DK, Do-
mingo E, Holland JJ, Moya A. 1996. Evolution of fitness in experimental
populations of vesicular stomatitis virus. Genetics 142:673–679.
63. Deymier MJ, Ende Z, Fenton-May AE, Dilernia DA, Kilembe W, Allen SA,
Borrow P, Hunter E. 2015. Heterosexual transmission of subtype C HIV-1
selects consensus-like variants without increased replicative capacity or
interferon- resistance. PLoS Pathog 11(9):e1005154. https://doi.org/10
.1371/journal.ppat.1005154.
64. Derdeyn CA, Hunter E. 2008. Viral characteristics of transmitted HIV. Curr
Opin HIV AIDS 3:16–21. https://doi.org/10.1097/COH.0b013e3282f2982c.
65. Votteler J, Neumann L, Hahn S, Hahn F, Rauch P, Schmidt K, Studtrucker
N, Solbak SM, Fossen T, Henklein P, Ott DE, Holland G, Bannert N,
Schubert U. 2011. Highly conserved serine residue 40 in HIV-1 p6
regulates capsid processing and virus core assembly. Retrovirology 8:11.
https://doi.org/10.1186/1742-4690-8-11.
66. Fujii K, Munshi UM, Ablan SD, Demirov DG, Soheilian F, Nagashima K,
Stephen AG, Fisher RJ, Freed EO. 2009. Functional role of Alix in HIV-1
replication. Virology 391:284–292. https://doi.org/10.1016/j.virol.2009.06
.016.
67. Patil A, Bhattacharya J. 2012. Natural deletion of L35Y36 in p6 gag
eliminate LYPXnL/ALIX auxiliary virus release pathway in HIV-1 subtype
C. Virus Res 170:154–158. https://doi.org/10.1016/j.virusres.2012.08.020.
68. Strack B, Calistri A, Craig S, Popova E, Göttlinger HG. 2003. AIP1/ALIX is
a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding.
Cell 114:689–699. https://doi.org/10.1016/S0092-8674(03)00653-6.
69. Alexander L, Weiskopf E, Greenough TC, Gaddis NC, Auerbach MR, Malim
MH, O’Brien SJ, Walker BD, Sullivan JL, Desrosiers RC. 2000. Unusual
polymorphisms in human immunodeficiency virus type 1 associated
with nonprogressive infection. J Virol 74:4361–4376. https://doi.org/10
.1128/JVI.74.9.4361-4376.2000.
70. Aralaguppe SG, Winner D, Singh K, Sarafianos SG, Quiñones-Mateu ME,
Sönnerborg A, Neogi U. 2017. Increased replication capacity following
evolution of PYxE insertion in Gag-p6 is associated with enhanced
virulence in HIV-1 subtype C from East Africa. J Med Virol 89:106–111.
https://doi.org/10.1002/jmv.24610.
71. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ,
MacDonald KS, Ngugi EN, Plummer FA. 1996. Resistance to HIV-1 infec-
tion among persistently seronegative prostitutes in Nairobi, Kenya. Lan-
cet 348:1347–1351. https://doi.org/10.1016/S0140-6736(95)12269-2.
72. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N,
Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN. 2011.
Impact of CD8 T-cell activation on CD4 T-cell recovery and mortality
in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 25:
2123–2131. https://doi.org/10.1097/QAD.0b013e32834c4ac1.
73. Ndung’u T, Sepako E, McLane MF, Chand F, Bedi K, Gaseitsiwe S, Doualla-
Bell F, Peter T, Thior I, Moyo SM, Gilbert PB, Novitsky VA, Essex M. 2006.
HIV-1 subtype C in vitro growth and co-receptor utilization. Virology
347:247–260. https://doi.org/10.1016/j.virol.2005.11.047.
74. Brockman MA, Tanzi GO, Walker BD, Allen TM. 2006. Use of a novel GFP
reporter cell line to examine replication capacity of CXCR4- and CCR5-
tropic HIV-1 by flow cytometry. J Virol Methods 131:134–142. https://
doi.org/10.1016/j.jviromet.2005.08.003.
75. de Oliveira T, Deforche K, Cassol S, Rambaut A, Vandamme AM.
Stanford University HIV Drug Resistance Database: Rega HIV-1 sub-
typing tool—version 2.0. http://www.bioafrica.net/rega-genotype/
html/subtyping.html. Accessed 7 April 2014.
76. Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to
estimate large phylogenies by maximum likelihood. Syst Biol 52:
696–704. https://doi.org/10.1080/10635150390235520.
77. Huang KH, Goedhals D, Carlson JM, Brockman MA, Mishra S, Brumme ZL,
Hickling S, Tang CS, Miura T, Seebregts C, Heckerman D, Ndung’u T,
Walker B, Klenerman P, Steyn D, Goulder P, Phillips R, Bloemfontein-
Oxford Collaborative Group, van Vuuren C, Frater J. 2011. Progression to
AIDS in South Africa is associated with both reverting and compensatory
viral mutations. PLoS One 6(4):e19018. https://doi.org/10.1371/journal
.pone.0019018.
78. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a
human cell line transformed by DNA from human adenovirus type 5. J
Gen Virol 36:59–74. https://doi.org/10.1099/0022-1317-36-1-59.
79. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide
studies. Proc Natl Acad Sci U S A 100:9440–9445. https://doi.org/10
.1073/pnas.1530509100.
80. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA,
Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander
C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman
D, Mallal S. 2009. HLA-associated immune escape pathways in HIV-1
subtype B Gag, Pol and Nef proteins. PLoS One 4(8):e6687. https://doi
.org/10.1371/journal.pone.0006687.
Kiguoya et al. Journal of Virology
July 2017 Volume 91 Issue 13 e00253-17 jvi.asm.org 20
 o
n
 July 3, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
